Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cephalon drug shown to reduce breakthrough cancer pain
According to the company, cancer breakthrough pain is a common yet under treated component of chronic pain which is characterized by its fast onset. “For breakthrough pain, you
According to the company, cancer breakthrough pain is a common yet under treated component of chronic pain which is characterized by its fast onset. “For breakthrough pain, you
According to data referred to by Barr, the drug had annual sales of approximately $346 million for the twelve months ended March 2006. Nasacort AQ (triamcinolone acetonide) nasal
The companies also plan to pursue RNAi-based therapeutics against chronic obstructive pulmonary disease (COPD) and allergic rhinitis. Sirna will provide GSK with optimized and formulated siRNAs against targets
Palatin and King are jointly developing the drug for the treatment of both male and female sexual dysfunction. The primary objective of these two dose-ranging clinical trials is
This is only the second biosimilar product to receive EU marketing authorization from the European Commission. Biopartners in-licensed Valtropin from LG Life Sciences and has commercialization rights for
The standard chemotherapy for the condition is bacillus calmette-guerin (BCG), a live, attenuated strain of mycobacterium bovis, a therapy that is often associated with treatment-limiting side effects. In
In the study the 24-hour blood pressure profile of HCT 3012 and naproxen, a commonly used anti-inflammatory drug, will be compared. The anti-inflammatory agents currently used in the
The phase I trial is a placebo controlled, randomized, dose escalating study, which will evaluate the safety, tolerability and antiviral activity of single and multiple doses of XTL-2125.
The collaboration aims to advance the performance of cell-based ion channel assays in screening applications. “We are pleased that AstraZeneca sees the value of our microfluidic-based solutions for
The research appears in the Journal of Biological Chemistry, an American Society for Biochemistry and Molecular Biology journal. Any new drugs that could be developed to block this